How does minimal residual disease (MRD) testing affect treatment decisions?

 

In this video, Dr. Brian G.M. Durie explains why MRD-negative status and MRD-positive status are not clear indicators for next steps in a myeloma patient’s treatment.

BOTTOM LINE:
MRD-testing is not yet recommended for routine testing, yet the results can be reassuring to patients.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org